Dupilumab for Eosinophilic Esophagitis in Patients 1 to 11 Years …
Jun 26, 2024 · In the current trial, we evaluated dupilumab in children 1 to 11 years of age with active eosinophilic esophagitis that was refractory to proton-pump inhibitor therapy. Methods. Trial Design...
How New Drug Approvals are Reshaping Treatment for Eosinophilic Esophagitis
February 27, 2024. The FDA has approved two medications for the treatment of eosinophilic esophagitis (EoE)—the first oral medication tailored for adults and the exclusive therapeutic option for children.
Dupilumab in Adults and Adolescents with Eosinophilic Esophagitis
Dec 21, 2022 · Dupilumab, a fully human monoclonal antibody, blocks interleukin-4 and interleukin-13 signaling, which have key roles in eosinophilic esophagitis. Methods.
FDA Approves First Treatment for Eosinophilic Esophagitis, a …
SILVER SPRING, Md., May 20, 2022 /PRNewswire/ -- Today, the U.S. Food and Drug Administration approved Dupixent (dupilumab) to treat eosinophilic esophagitis (EoE) in adults and pediatric...
Dupilumab in Adults and Adolescents with Eosinophilic Esophagitis
Dec 22, 2022 · Among patients with eosinophilic esophagitis, subcutaneous dupilumab administered weekly improved histologic outcomes and alleviated symptoms of the disease. (Funded by Sanofi and Regeneron Pharmaceuticals; ClinicalTrials.gov number, NCT03633617.).
Press Room - Sanofi US News
Dec 21, 2022 · Positive Dupixent® (dupilumab) Phase 3 results in adults and adolescents with eosinophilic esophagitis published in the New England Journal of Medicine. Dupixent 300 mg weekly showed significant histological disease remission and improvement in symptoms of the disease compared to placebo.
Clinical guidance for the use of dupilumab in eosinophilic esophagitis
Dupilumab is currently approved for patients 12 years and older with a minimum weight of 40 kg. This clinical guideline is meant to advise readers on how to frame the management of patients with EoE given the addition of the first FDA-approved treatment for EoE for clinical use.
FDA Approves Dupixent® (dupilumab) as First Treatment for …
May 20, 2022 · Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the U.S. Food and Drug Administration (FDA) has approved Dupixent ® (dupilumab) 300 mg weekly to treat patients with...
Among patients with eosinophilic esophagitis, subcutaneous dupilumab adminis-tered weekly improved histologic outcomes and alleviated symptoms of the dis-ease.
Dupixent® (dupilumab) Eosinophilic Esophagitis Trial Meets …
May 22, 2020 · Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced positive results from Part A of the pivotal Phase 3 trial evaluating Dupixent ® (dupilumab) in patients 12 years and older with eosinophilic esophagitis (EoE). The trial met both of its co-primary endpoints, as well as all key secondary endpoints.
- Some results have been removed